What Could a New Drug Approval Mean for CLL Patients?

What Could a New Drug Approval Mean for CLL Patients?

Dr. William Wierda, medical director of the Department of Leukemia at the University of Texas MD Anderson Cancer Center, joins Patient Power to discuss the FDA approval of Venclexta (venetoclax) for use in CLL patients with the 17p deletion. Dr. Wierda reviews how the treatment works, its potential side effects and shares his perspective on what the approval could mean for a broader group of patients in the future. 

patientpower.info/video/wha...

2 Replies

oldestnewest
  • A wonderful video with a fantastic Dr. 

    Jeff 

  • Thanks! He is great!! 

You may also like...